Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023)
Sarepta Therapeutics' quarterly Current Leases came in at $17.8 million in Q4 2023, up 15.21% year-on-year from $15.5 million in Q4 2022, and up 15.21% quarter-over-quarter from $15.5 million in Q4 2022.
Sarepta Therapeutics has reported Current Leases for 2 years, with the latest figure at $17.8 million in Q4 2023.
- For the quarter ending Q4 2023, Current Leases rose 15.21% year-over-year to $17.8 million; the trailing twelve-month figure through Dec 2023 stood at $17.8 million (up 15.21% YoY), and the FY2023 full-year result was $17.8 million, up 15.21% from the prior year.
- Current Leases for Q4 2023 stood at $17.8 million, up from $15.5 million in the prior quarter.
- The five-year high for Current Leases was $17.8 million in Q4 2023, with the low at $15.5 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 17.85 Mn |
| Dec 31, 2022 | 15.49 Mn |